First-line crizotinib versus chemotherapy in ALK-positive lung cancer

New England Journal of Medicine

Volumn 371, Issue 23, 2014, Pages 2167-2177

  Solomon, Benjamin J ^a   Mok, Tony ^b   Kim, Dong Wan ^d   Wu, Yi Long ^c   Nakagawa, Kazuhiko ^e   Mekhail, Tarek ^f   Felip, Enriqueta ^g   Cappuzzo, Federico ^h   Paolini, Jolanda ⁱ   Usari, Tiziana ⁱ   Iyer, Shrividya ^j   Reisman, Arlene ^k   Wilner, Keith D ⁱ   Tursi, Jennifer ⁱ   Blackhall, Fiona ^l  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d Seoul National University Hospital   (South Korea)

^e KINKI UNIVERSITY   (Japan)

^f FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h ISTITUTO TOSCANO TUMORI   (Italy)

ⁱ PFIZER INC   (United States)

^j Pfizer Ltd   (United States)

^k Pfizer Global Innovative Pharma Business   (United States)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CISPLATIN; CRIZOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; CARBOPLATIN; GLUTAMIC ACID DERIVATIVE; GUANINE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84918804764     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1408440     Document Type: Article

References (33)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
2. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-203.
3. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
4. Camidge DR, Doebele RC. Treating ALK-positive lung cancer - early suc-cesses and future challenges. Nat Rev Clin Oncol 2012; 9: 268-77.
5. Blackhall FH, Peters S, Bubendorf L, et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I-III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014; 32: 2780-7.
6. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Mol Cancer Ther 2007; 6: 3314-22.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
8. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-9.
9. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: Suppl. abstract.
10. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-94.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
13. Abbott Molecular. Vysis ALK Break Apart FISH Probe Kit package insert, 2011 (http://www .abbottmolecular .com/static/cms-workspace/pdfs/US/Vysis-ALK- FISH-Probe-Kit-PI .pdf).
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
17. Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer 2002; 38: Suppl 4: S125-S133.
18. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQLC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-42.
19. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
20. Robins JM, Tsiatis A. Correcting for non-compliance in randomized trials using rank-preserving structural failure time models. Commun Stat Theory Methods 1991; 20: 2609-31.
21. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3: 319-36.
22. White IR, Babiker AG, Walker S, Darbyshire JH. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. Stat Med 1999; 18: 2617-34.
23. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-3.
24. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
25. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
26. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
27. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non- small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
28. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
29. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011; 6: 774-80.
30. Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 2013; 24: 59-66.
31. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-55.
32. Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line - is there a difference J Clin Oncol 2013; 31: 1081-8.
33. Shaw AT, Solomon BJ, Mok T, et al. Effect of treatment duration on incidence of adverse events (AEs) in a phase III study of crizotinib versus chemotherapy in advanced ALK-positive non-small cell lung cancer (NSCLC). Presented at the 15th World Conference on Lung Cancer, Sydney, October 27-30, 2013. abstract.